Replies to post #127988 on Biotech Values

[iwfal]

I assume you're not counting an authorized generic from SNY as being a "third" generic.
Correct.

Even if it were considered a "third" generic... it would just serve as a large inducement to Sanofi not to launch an authorized generic.